WallStSmart

Cardinal Health Inc (CAH)vsThermo Fisher Scientific Inc (TMO)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Cardinal Health Inc generates 455% more annual revenue ($250.74B vs $45.20B). TMO leads profitability with a 15.1% profit margin vs 0.6%. CAH appears more attractively valued with a PEG of 1.25. TMO earns a higher WallStSmart Score of 62/100 (C+).

CAH

Hold

47

out of 100

Grade: D+

Growth: 4.7Profit: 4.5Value: 7.3Quality: 5.8
Piotroski: 4/9Altman Z: 4.30

TMO

Buy

62

out of 100

Grade: C+

Growth: 4.7Profit: 7.0Value: 4.7Quality: 5.3
Piotroski: 3/9
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

CAHUndervalued (+73.9%)

Margin of Safety

+73.9%

Fair Value

$859.62

Current Price

$183.65

$675.97 discount

UndervaluedFair: $859.62Overvalued
TMOOvervalued (-13.7%)

Margin of Safety

-13.7%

Fair Value

$408.97

Current Price

$465.00

$56.03 premium

UndervaluedFair: $408.97Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

CAH2 strengths · Avg: 9.0/10
Altman Z-ScoreHealth
4.3010/10

Safe zone — low bankruptcy risk

Free Cash FlowQuality
$1.68B8/10

Generating 1.7B in free cash flow

TMO1 strengths · Avg: 9.0/10
Market CapQuality
$176.32B9/10

Large-cap with strong market position

Areas to Watch

CAH4 concerns · Avg: 3.3/10
P/E RatioValuation
28.2x4/10

Moderate valuation

Return on EquityProfitability
0.0%3/10

ROE of 0.0% — below average capital efficiency

Profit MarginProfitability
0.6%3/10

0.6% margin — thin

Operating MarginProfitability
1.4%3/10

Operating margin of 1.4%

TMO3 concerns · Avg: 3.7/10
PEG RatioValuation
1.564/10

Expensive relative to growth rate

P/E RatioValuation
26.1x4/10

Moderate valuation

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Comparative Analysis Report

WallStSmart Research

Bull Case : CAH

The strongest argument for CAH centers on Altman Z-Score, Free Cash Flow. Revenue growth of 11.0% demonstrates continued momentum. PEG of 1.25 suggests the stock is reasonably priced for its growth.

Bull Case : TMO

The strongest argument for TMO centers on Market Cap. Profitability is solid with margins at 15.1% and operating margin at 17.9%.

Bear Case : CAH

The primary concerns for CAH are P/E Ratio, Return on Equity, Profit Margin. Thin 0.6% margins leave little buffer for downturns.

Bear Case : TMO

The primary concerns for TMO are PEG Ratio, P/E Ratio, Piotroski F-Score.

Key Dynamics to Monitor

CAH profiles as a value stock while TMO is a mature play — different risk/reward profiles.

TMO carries more volatility with a beta of 0.88 — expect wider price swings.

CAH is growing revenue faster at 11.0% — sustainability is the question.

CAH generates stronger free cash flow (1.7B), providing more financial flexibility.

Bottom Line

TMO scores higher overall (62/100 vs 47/100), backed by strong 15.1% margins. CAH offers better value entry with a 73.9% margin of safety. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Cardinal Health Inc

HEALTHCARE · MEDICAL DISTRIBUTION · USA

Cardinal Health, Inc. is an American multinational health care services company.

Visit Website →

Thermo Fisher Scientific Inc

HEALTHCARE · DIAGNOSTICS & RESEARCH · USA

Thermo Fisher Scientific is an American provisioner of scientific instrumentation, reagents and consumables, and software and services to healthcare, life science, and other laboratories in academia, government, and industry (including in the biotechnology and pharmaceutical sectors). Based in Waltham, Massachusetts, Thermo Fisher was created in 2006 by the merger of Thermo Electron and Fisher Scientific, to form a company with US$ 9 billion in combined revenues.

Visit Website →

Want to dig deeper into these stocks?